T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the frequency of occurrence, severity, and response to treatment by a
chemical agent, notably the dimerizer AP1903 (Bellicum Pharmaceuticals compagny), in the case
of acute Graft versus Host Disease (aGvHD) occurring after the administration of
T-lymphocytes expressing iCASP9 and concomitantly to a bone marrow graft depleted in B- and
T-lymphocytes
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Collaborators:
Bellicum Pharmaceuticals Etablissement Français du Sang